Patient Programs Provider Education
While 2017 was a busy year for biosimilar approvals by the FDA, Rick Lozano, vice president of biosimilars and integrated business development at AmerisourceBergen, feels that the biggest developments in biosimilars were those being made outside the regulatory or clinical spheres. In an interview with The Center for Biosimilars, Lozano said that “There are distractions and defense strategies in the market that continue to be slowing the pace” of bringing biosimilars to the market." Lozano reported that, in his work at AmerisourceBergen, he does not see biosimilars as fitting under a typical brand-name drug platform or under a generic drug platform; instead, he is focused on developing a unique approach to these products to help them thrive in the marketplace.
For the full article, visit The Center for Biosimilars.